

# Long Noncoding RNA and Cancer: A New Paradigm

Arunoday Bhan, Milad Soleimani, and Subhrangsu S. Mandal



## Abstract

In addition to mutations or aberrant expression in the protein-coding genes, mutations and misregulation of noncoding RNAs, in particular long noncoding RNAs (lncRNA), appear to play major roles in cancer. Genome-wide association studies of tumor samples have identified a large number of lncRNAs associated with various types of cancer. Alterations in lncRNA expression and their mutations promote tumorigenesis and metastasis. lncRNAs may exhibit tumor-suppressive and -pro-

moting (oncogenic) functions. Because of their genome-wide expression patterns in a variety of tissues and their tissue-specific expression characteristics, lncRNAs hold strong promise as novel biomarkers and therapeutic targets for cancer. In this article, we have reviewed the emerging functions and association of lncRNAs in different types of cancer and discussed their potential implications in cancer diagnosis and therapy. *Cancer Res*; 77(15); 3965–81. ©2017 AACR.

## Introduction

Cancer is a complex disease associated with a variety of genetic mutations, epigenetic alterations, chromosomal translocations, deletions, and amplification (1). Noncoding RNAs (ncRNA) are an emerging class of transcripts that are coded by the genome but are mostly not translated into proteins (2). Although not translated, ncRNAs are crucial players in a variety of cellular and physiologic functions (3). In particular, long noncoding RNAs (lncRNAs that are >200 nt long) play key roles in regulating chromatin dynamics, gene expression, growth, differentiation, and development (4). It is now well recognized that more than 75% of the human genome is functional and encodes large numbers of ncRNAs (5). On the basis of the ENCODE project, it is estimated that the human genome encodes more than 28,000 distinct long noncoding RNAs (lncRNA), many of which are still being discovered and are yet to be annotated (6). While understanding the functions of so many lncRNAs and their detailed characterization are challenging tasks, analysis of transcriptome profiles using next-generation sequencing in the last few years has revealed that thousands of lncRNAs are aberrantly expressed or mutated in various cancers (7).

Although lncRNAs are emerging as a major class of noncoding transcripts, the discovery of tremendously large numbers of lncRNAs and their diverse functions and complexity pose a major challenge to effectively classify them in different categories. At this point, lncRNAs are broadly classified on the basis of their genomic localization, modes of action, and function. Intronic lncRNAs originate from the introns of protein-coding genes; intergenic

lncRNAs (lincRNA) originate from the region between two protein-coding genes; enhancer lncRNAs (elncRNA) originate from the promoter enhancer regions; bidirectional lncRNAs are localized within the vicinity of a coding transcript of the opposite strand; sense-overlapping lncRNAs overlap with one or more introns and exons of different protein-coding genes in the sense strand of the DNA; antisense transcripts originate from the antisense strands of the DNA, and they may or may not be complementary to protein coding sequences in the sense-strand (7, 8). Functionally, lncRNAs are classified as signaling, decoy, guide, and scaffold lncRNAs (9). Signaling lncRNAs are associated with specific signaling pathways and their expression indicates an active signaling event, irrespective of their roles (direct/indirect) in the signaling process (9). For example, the expression of XIST signals X-inactivation in females (10). Decoy lncRNAs act like molecular sinks for transcription factors and repressors. They interact with and titrate away transcription factors from binding to the target gene promoters facilitating gene activation or silencing (9). Examples of decoy lncRNAs include GAS5 (growth arrest specific 5), TERRA (telomeric repeat-containing RNA), and others. (9). Guide lncRNAs bind to the regulatory or enzymatically active protein complexes and direct them to specific target gene promoters or genomic loci regulating downstream signaling events and gene expressions. Examples of guide lncRNAs include AIR, CCND1 (cyclin D promoter associated lncRNA), lincRNA-p21, and others (8, 9). Scaffold lncRNAs act as a central platform to which various protein complexes tether and get directed to specific genomic location or target gene promoter—regulating gene expression and chromosomal dynamics. Examples of scaffold lncRNAs are HOTAIR, TERC, and others.

Beyond traditional ncRNAs, circular RNAs (circRNA) are also emerging as a novel class of endogenous noncoding RNAs that form covalently closed continuous loops instead of traditional linear forms. CircRNAs are conserved across species and are found to be associated with a variety of important biological processes and human diseases including cancer. CircRNAs appear to function as miRNA sponges and are involved in the regulation of mRNA splicing, transcription, and gene expression (11, 12). Generally, circRNAs are classified as exonic, intronic, and

Gene Regulation and Epigenetics Research Lab, Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas.

A. Bhan and M. Soleimani contributed equally to this article.

**Corresponding Author:** Subhrangsu S. Mandal, Department of Chemistry and Biochemistry, University of Texas at Arlington, 700 Planetarium Place, Arlington, TX 76019. Phone: 817-272-3804; Fax: 817-272-3808; E-mail: smandal@uta.edu

doi: 10.1158/0008-5472.CAN-16-2634

©2017 American Association for Cancer Research.

retained-intronic circRNAs. They may be derived from exons, introns, untranslated regions, antisense transcripts, and intergenic regions. CircRNA biogenesis has been explained by various models, incorporating a range of spliceosomes and RNA-binding proteins. The most accepted model suggests that circRNA biogenesis involves joining of a 5' splice site and a 3' splice site as the result of back splicing (13, 14). Because of their unique structure, circRNAs are resistant to nucleases and are stable with a relatively long half-life. They may exist in tissues, serum, and urine, indicating their potential as novel biomarkers for human cancer. CircRNAs are implicated in a variety of cancers including laryngeal cancer, gastric cancer, hepatocellular cancer, bladder cancer, and esophageal cancer, among others (11, 15, 16). For example, circRNA ciRS-7, which acts as a sponge for miR-7, is involved in promoting colorectal cancer through inhibiting the repression of oncogenes such as YY1 by tumor suppressor miR-7 (15). CiRS-7 is an endogenous circRNA highly expressed in the brain and transcribed antisense to the *CDR1* (cerebellum degeneration-related antigen 1) gene (12). CircRNAs such as circ-ITCH, hsa\_circ\_002059, and hsa\_circ\_0001649 are downregulated in colorectal cancer, gastric cancer, and hepatocellular cancer, whereas circ-VCAN, circTCF25, and circ-KLDGC10 are upregulated in glioma, bladder cancer, and hepatocellular cancer (11, 12, 16–18). CircRNAs such as ci-ankrd52 and circular -ANRIL are examples of circular lncRNAs (19, 20). Similar to lncRNAs, many circRNAs display aberrant expression in various cancers and possess strong promise toward development of novel biomarkers and therapeutics.

Thus, in addition to protein-coding genes, ncRNAs, in particular lncRNAs, are rapidly emerging as a novel class of transcripts associated with a variety of cellular and biological processes including gene regulation and chromatin dynamics. They are abundantly expressed and widely associated with a variety of cancers, and the aberrant expression and mutations are closely linked to tumorigenesis, metastasis, and tumor stage (21–23). Moreover, they are specifically expressed in certain types of cancer and detected in circulating blood and/or urine (24–26). lncRNAs are a novel class of potential biomarkers and therapeutic targets for the treatment of cancer. In this article, we have reviewed the functions of various lncRNAs in different types of cancer and discussed their potential implications in diagnosis and therapy (Fig. 1).

## **lncRNAs in Prostate Cancer**

Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths in American men. The American Cancer Society estimates about 181,000 new cases of prostate cancer and 26,000 deaths from prostate cancer in the United States in 2016. There is an urgent need to develop novel diagnostic biomarkers and effective therapies for prostate cancer. Genome-wide RNA-Seq analyses identified many lncRNAs that are up- or downregulated in prostate cancer (27). Several lncRNAs, such as PCA3, PCGEM1, and PCAT-1, are highly specific to prostate cancer (Fig. 1; Table 1; ref. 28).

### **PCA3**

PCA3 (prostate cancer antigen 3; a.k.a., DD3), a steroid receptor-regulated lncRNA transcribed from 9q21.22, is overexpressed in 95% of prostate cancer cases and is detected with high specificity in the urine of patients with malignant and benign prostate

cancer (29–31; Fig. 1; Tables 1 and 2). PCA3 and Hedgehog receptor PTCH (also implicated in prostate cancer) are highly upregulated in the circulating prostate cancer cells of androgen refractory patients (32–34). Prune2 (a tumor suppressor and a target of PCA3) and PCA3 expressions are inversely correlated in prostate cancer (34). PCA3 binds to PRUNE2-pre-mRNA to form a double-stranded RNA duplex that recruits adenosine deaminase (ADA), inducing RNA editing through acting on RNA (ADAR) proteins (34).

### **PCGEM1**

PCGEM1 (prostate cancer gene expression marker 1) is a 1.6-kb long lncRNA from the 2q32 locus. It is a highly prostate tissue-specific and androgen-regulated lncRNA that is overexpressed in prostate cancer and promotes cell proliferation and colony formation (Fig. 1; Table 1; refs. 35–37). PCGEM1 expression inhibits doxorubicin-induced apoptosis and promotes chemoresistance via inhibition of PARP cleavage and delaying the induction of tumor suppressors p53 and p21 (36). Another lncRNA PRNCR1 (prostate cancer noncoding RNA1), in conjunction with PCGEM1, regulates gene expression by promoting epigenetic modifications (36). PRNCR1 binds to acetylated androgen receptor (AR) at the enhancer, and recruits histone H3K79 methyltransferase DOT1L (disruptor of telomeric silencing 1-like), which methylates AR that aids in the recruitment of PCGEM1 to the AR N-terminal and modulates target gene expression (35). Similarly, PCGEM1 recruits the Pygopus family PHD finger 2 (PYGO2) to the enhancer-promoter regions of AR gene and regulates AR-induced gene expression (38).


### **PCAT-1**

PCAT-1 (prostate cancer-associated ncRNA transcript 1) is a 7.8-kb long intergenic lncRNA (originating from 8q24 locus) that is overexpressed in and highly specific to high-grade localized and metastatic prostate cancer (Fig. 1; Tables 1 and 2; refs. 28, 38, 39). It is independent of chromosome 8q24 amplification that is often observed in other cancers. There is a converse correlation between the expression of PCAT-1 and EZH2 [a histone H3K27-specific methyltransferase and interacting component of polycomb repressive complex 2 (PRC2); ref. 27]. EZH2 (enhancer of zeste homolog 2) knockdown upregulates PCAT-1 (27). PRC2 binds the PCAT-1 promoter and suppresses PCAT-1 expression (27). PCAT-1 induces cell proliferation and downregulates the expression of genes including tumor suppressor gene *BRCA2*. PCAT-1 sensitizes prostate cancer cells toward PARP1 inhibitors. PCAT-1 posttranscriptionally upregulates c-Myc that promotes prostate cancer cell proliferation (28, 38).

Various other lncRNAs including MALAT1, GAS5, PCAT6, PCAT-18, lincRNA-p21, PRNCR1, TRPM2, CTBP1-AS, ANRIL, PVT1, and SCHLAP1 are also linked to prostate cancer (Fig. 1; Table 1; refs. 28, 38). PCAT-18 is a highly prostate-specific transcript upregulated in prostate cancer and regulated by AR (28). CTBP1-AS is an androgen-responsive lncRNA and an antisense transcript of the *CTBP1* gene (40). Overexpression of CTBP1-AS inhibits the expression of cell-cycle regulators such as p53 and Smad3 in prostate cancer cells, resulting in cell proliferation (41, 42).

## **Breast Cancer**

Breast cancer is the most common and the second deadliest cancer among women. It is estimated that



Downloaded from <http://aacrjournals.org/cancerres/article-pdf/77/15/3965/2753524/3965.pdf> by guest on 12 February 2025

**Figure 1.**  
LncRNAs associated with various types of cancer.

246,660 new cases and 40,450 deaths occurred from breast cancer in the United States in 2016. LncRNAs implicated in breast cancer include HOTAIR, ANRIL, ZFAS1, HOTAIRM1,

NEAT1, DANCR, HIF1A-AS, XIST, TOPORS-AS1, LSINCT-5, PVT1, MALAT1, and LNP1, among others (Fig. 1; Tables 1 and 2; refs. 43, 44).

**Table 1.** LncRNAs: their mechanism of action and significance in cancer

LncRNA	Cancer type	Mechanism of action and function	References
PCA3 (a.k.a. DD3)	Prostate	Steroid receptor-regulated lncRNA; induces RNA editing via interaction with PRUNE2-pre-mRNA to form a double-stranded RNA duplex and ADAR proteins; knockdown results in reduced cell growth and survival and induction of apoptotic cells; (↑)	29, 31, 33, 34, 258
PCGEM1	Prostate	Promotes colony formation, cell proliferation; promotes chemoresistance via inhibition of PARP cleavage and delaying the induction of tumor suppressors p53 and p21; regulates AR target genes expression, in conjunction with lncRNA PRNCR1, AR, histone methylase DOT1L; and Pygopus family PHD finger 2 (PYGO2); knockdown results in reduced proliferation and increased apoptosis; (↑)	35-37
PCAT-1	Prostate	Promotes cell proliferation, downregulates genes and tumor suppressor genes; sensitizes prostate cancer cells towards PARP1 inhibitors; posttranscriptionally upregulates c-Myc; (↑)	27, 39
HOTAIR	Breast, hepatocellular, colorectal, pancreatic, lung, ovarian	Scaffolding lncRNA, silences genes via interaction with PRC2 and LSD1, aids in protein degradation via interaction with E3 ubiquitin ligases; knockdown reduces tumor invasiveness, disrupts of EMT; (↑)	45-53, 57, 58, 262
ANRIL	Breast, gastric, lung, liver	Controls cell proliferation and senescence via regulating tumor suppressors CDKN2A/B; represses the INK4A locus via interaction with CBX7 and PRC2; knockdown lowers multidrug resistance, reduces proliferation, and invasiveness; (↑)	66-78
MALAT1 (a.k.a. NEAT2)	Lung, prostate, breast, colorectal, liver, gastric, leukemia, brain, renal	Undergoes processing to produce a short and long RNA transcript; localized into nuclear speckles; influences SR-protein phosphorylation and modulates alternative splicing; regulates of EMT gene expression; associates with SUZ12 and regulates N-cadherin and E-cadherin expression; knockdown reduces cell growth, invasion, and migration, and differentiation into cystic tumors; (↑)	83-90
NEAT1	Leukemia, ovarian	Regulates ADARB2 expression via protein sequestration into paraspeckles; knockdown results in inhibition of cell growth; (↑)	95, 96
H19	Bladder, brain, gastric, renal, lung, ovarian, colorectal, pancreatic	Pivotal in embryonic development and tumorigenesis; maternally expressed and paternally imprinted; precursor of miRNAs (miR-675), P53 represses the H19 gene and the H19-derived miR-675 inhibits p53; interacts with EZH2, MBD1 and induces gene repression; knockdown reduces tumor size and metastasis; (↑)	1, 100-116
KCNQ10T1	Colorectal, hepatocellular, pediatric adrenocortical; Beckwith-Wiedemann syndrome	Paternally imprinted; interacts with PRC1, PRC2, and G9a and silences KCNQ1 via induction in histone and DNA methylation; imprinting disruption of the CDKN1C/KCNQ10T1 domain is involved in the development of both BWS and cancer; knockdown results in loss of imprinting in the 5'-domain of KCNQ10T1; (↑)	119-123
T-UCRs	Colorectal, Barrett's adenocarcinoma, bladder, liver	CpG-island hypermethylation induced T-UCR silencing is common in many tumors; inhibits miR-596 via interaction with YY1, inhibits miR-193b; overexpression inhibits migration and invasion; (↑)	128-130
CCAT1	Colorectal, leukemia, gastric, Lung, esophageal squamous cell carcinoma	Acts as a sponge for let-7 and miR-155, regulates c-Myc, HOXB13, SPRY4; knockdown reduces cell proliferation and migration; (↑)	135, 137
HULC	Hepatocellular, pancreatic	Acts as a miRNA sponge and sequesters miR-372; potential biomarker for HCC; knockdown inhibits cell proliferation and increases chemosensitivity; (↑)	141, 142
HEIH	Hepatocellular	Linked with hepatitis-B-virus associated HCC recurrence; regulates cell-cycle-regulatory genes p15, p16, p21 via interaction with EZH2; knockdown reduces cell proliferation and suppresses tumor growth (↑)	139, 145, 146
HOTTIP	Prostate, liver, pancreatic	Controls the HOXA locus via interaction with WDR5/MLL; knockdown suppresses chemoresistance, and mesenchymal characteristics; (↑)	150-152
UCA1	Bladder, leukemia, ovarian, breast	Potential urine biomarker; promotes chemoresistance; recruits SWI/SNF to the TCF7 promoter, induces Wnt/ $\beta$ -catenin signaling and ER redistribution; knockdown increases chemosensitivity, reduces cell migration and tumor size; (↑)	157, 158
DLEU1, DLEU2	Leukemia	Deleted in lymphocytic leukemia; regulate NF- $\kappa$ B activity, acts as a precursor for miR-15a and miR-16-1 in leukemia; (↓)	164, 165

(Continued on the following page)

**Table 1.** LncRNAs: their mechanism of action and significance in cancer (Cont'd)

LncRNA	Cancer type	Mechanism of action and function	References
LUNAR1	Leukemia, B-cell lymphoma	Promotes T-ALL growth by inducing IGF1R expression, regulates IGF1R via interaction with mediator complex; knockdown reduces cell proliferation and viability; (↑)	166, 167
BGL3	Leukemia	Regulates Bcr-Abl through sponging miRNAs (miR-17, miR-93, miR-20a, miR-20b, miR-106a, and miR-106b) and via c-Myc-dependent DNA methylation; (↓)	168
HOTAIRM1	Breast, leukemia, colorectal	Controls myeloid autophagy and maturation via interaction with PRC2 and UTX/MLL; knockdown results in retardation of myeloid cell differentiation; (↑)	170-172
XIST	Ovarian, leukemia	Inactivates X chromosome via coating and interaction with PRC1/2, YY1, CTCF, etc.; knockdown results in enhanced sensitivity to Taxol; (↑)	174, 175
FERIL4	Gastric, endometrial	Regulates PTEN and the PI3K-AKT pathway by behaving as a ceRNA for miR-106a-5p; overexpression reduces cell growth and colony formation; (↓)	169, 195
NBAT1	Renal, neuroblastoma	Silences neuronal-specific NRSF/REST through association with PRC2; overexpression results in differentiation of neuronal precursors; (↓)	196, 197
GAS5	Breast, renal, prostate, endometrial	Acts as decoy for glucocorticoid receptor (GR), inhibits transcriptional induction by GR, causes growth arrest and apoptosis, induces PTEN via inhibiting miR-103; (↓)	198-200
TERRA	Pancreatic, cervical, gastric, breast	Facilitates heterochromatin formation via interaction with TRF1 and TRF2, aids in telomerase function by providing a RNA template; (↓)	205-207
ZFAS1	Breast, colorectal, gastric, liver	Interacts with CDK1/cyclin B, EZH2, LSD1/CoREST, acts as a sponge for miR-150, promotes cell proliferation; knockdown results in inhibition of cell proliferation, migration, and colony formation; (↑)	209-211
PVT1	Breast, pancreatic, ovarian, gastric, lung	Promote proliferation via interaction with NOP2 with the aid of TGFβ1, enhances c-Myc stability via inhibiting its phosphorylation; knockdown results in reduced cell proliferation and chemoresistance; (↑)	213-215
MEG3	Renal, gastric, ovarian, liver, lung, brain, bladder	Represses MDM2, aids in p53 accumulation, represses genomic loci of genes associated with TGFβ pathway via cooperating with PRC2; overexpression results in apoptosis and inhibition of proliferation; (↓)	218-221
TUG1	Bladder, gastric, lung	Silences cell-cycle-associated genes via interaction with PRC2; knockdown results in inhibition of cell proliferation, invasion, and colony formation; (↑)	2, 3, 275-277
Linc-RoR	Breast, pancreatic, hepatocellular, endometrial, nasopharyngeal	Induces epithelial-mesenchymal transition, drug resistance and invasiveness of cancer cells; promotes invasion, metastasis and tumor growth through activating ZEB1 pathway; (↑)	179

NOTE: ↑, upregulated in cancer (oncogenic); ↓, downregulated in cancer (tumor suppressor).

### HOTAIR

HOTAIR (HOX transcript antisense intergenic RNA) is one of the most well-studied lncRNAs that is overexpressed in a variety of cancers including breast, colorectal, hepatocellular, gastrointestinal, and non-small cell lung carcinomas (Table 1; refs. 4, 45-51). HOTAIR, a 2.2-kb antisense lncRNA, interacts with two major gene-silencing factors: PRC2 and LSD1 (lysine specific demethylase 1). PRC2 is a multiprotein complex comprised of EZH2 (H3K27-methylase), SUZ12, EED, and RbAp46/48 (52-54). LSD1 interacts with corepressors REST and CoREST (54, 55). H3K27-methylation by EZH2 and H3K4-demethylation by LSD1 are both critical to gene silencing (54). HOTAIR recruits PRC2 and LSD1 at the target gene, inducing gene silencing via H3K27-methylation and H3K4-demethylation (54, 56). BRCA1, a critical player in DNA damage response and breast cancer, also interacts with EZH2, which in turn interacts with HOTAIR (54, 57, 58). Thus, BRCA1 and HOTAIR are both interacting partners of EZH2 and may have competitive roles in gene expression and DNA damage response (59). HOTAIR is also implicated in assembling E3-ubiquitin ligases during protein degradation (4, 7, 53).

HOTAIR, EZH2, and LSD1 are all highly expressed in breast and other cancers. HOTAIR represses tumor suppressors such as PGR (progesterone receptor), PCDH10 (Protocadherin10), PCDHB5 (Protocadherin Beta 5), and JAM2 (Junctional Adhesion Molecule 2; ref. 52). Posttranslational functions of the HOTAIR have also been identified. HOTAIR induces ubiquitin-mediated proteolysis via interaction with E3 ubiquitin ligases Dzip3 and Mex3b, along with their respective ubiquitination substrates Ataxin-1 and Snurportin-1 (60). This leads to the degradation of Ataxin-1 and Snurportin-1 (60). Being an oncogenic lncRNA, its expression is correlated to tumor invasiveness and metastasis (53). HOTAIR serves as a diagnostic and prognostic marker for multiple cancers. HOTAIR also regulates the expression of miRNAs such as miR-130a (in gallbladder cancer cells) and others (4). Studies from our laboratory show that HOTAIR is required for the viability of breast cancer cells and its expression is transcriptionally regulated by estradiol via coordination of estrogen receptors (ER) and ER coregulators, such as the MLL (mixed lineage leukemia) family of histone methyltransferases, and CBP/p300 (45, 61-65). HOTAIR is also a target of endocrine disruption by estrogenic

**Table 2.** lncRNAs as cancer biomarkers

Cancer	lncRNA Biomarker	Potential implications	Site of detection	References
Prostate cancer	PCA3	Detection; Prognosis	Urine; Tumor	30, 225
	lincRNA-p21	Detection; Stratification	Urine	199
	PCAT-18	Metastasis	Plasma	28
	MALAT1	Risk of tumorigenesis; Detection	Urine; Plasma	240, 241
	PVT1	Aggressiveness	Tumor	226
Breast cancer	TRPM2	Early identification; aggressiveness	Tumor	227
	ZFAS1	Detection	Tumor	212
	HOTAIR	Detection	Serum	228
	RP11-445H22.4	Detection	Serum	242
	HIF1A-AS2; AK124454	Recurrence	Tumor	229, 230
Lung cancer	MALAT1	Early detection; Risk of metastasis	Whole blood; Tumor	87, 231, 232
	SPRY4-IT1; ANRIL; NEAT1	Early detection	Plasma	92
	UCA1	Detection	Plasma; Tumor	233
Colorectal cancer	HOTAIR	Risk of tumorigenesis	Tumor	234
	HOTAIR; CCAT1; CCAT2	Detection	Serum	235
	FERIL4	Recurrence; Metastasis	Plasma	236
	XLOC_006844; LOC152578; XLOC_000303	Risk of tumorigenesis	Plasma	237
Hepatocellular cancer	HOTAIR	Recurrence after transplant	Tumor	51
	uc001ncr; AX800134	Detection (especially early-stage)	Serum	143
	HULC; linc00152	Detection; Metastasis	Plasma	238
	RP11-160H22.5; XLOC014172; LOC149086, HEIH	Risk of tumorigenesis, prognostic factor for recurrence and survival	Plasma	239
	XLOC014172; LOC149086	Risk of metastasis		239
Bladder cancer	UCA1	Detection	Urine	243
	H19	Early recurrence	Tumor	100
	HOTAIR	Overall survival	Tumor	244
Leukemia	CRNDE	Identification of subtypes of AML (acute myeloid leukemia) (M2 or M3)	Bone marrow, Lymph nodes	245
Ovarian cancer	NEAT1	Invasiveness; Prognosis	Tumor	246
Renal cancer	LET; PVT1; PANDAR; PTENP1; LINC00963	Early detection	Serum	247
Cervical cancer	HOTAIR	Prognosis; Recurrence	Serum	248
Esophageal cancer	POU3F3; HNF1A-AS1; SPRY4-IT1	Early screening	Plasma	249
Gastric cancer	H19	Early screening	Plasma	250
	LINC00152	Detection; Invasion	Gastric juice; Tumor	251
	UCA1	Early detection; Prognosis prediction	Gastric juice; Tumor	252
	CUDR; LSINCT-5; PTENP1; AA174084	Detection; Early diagnosis	Serum; Tumor; Plasma; Gastric juice	253, 254

endocrine disruptors such as bisphenol-A (BPA) and diethylstilbestrol (DES) that may contribute to cancer (45, 61, 62).

#### ANRIL

ANRIL (antisense noncoding RNA in the INK4 locus; a.k.a. CDKN2B-AS) is encoded in the chromosome 9p21 region at the INK4 locus (Tables 1 and 2; refs. 66–78). Polymorphisms in the INK4 locus serve as a hotspot for a variety of diseases including cardiovascular disease, cancer, and diabetes. ANRIL is an antisense transcript of the *CDKN2B* gene (cyclin-dependent kinase inhibitor 2B) and controls cell proliferation and senescence via regulating its neighboring tumor suppressors *CDKN2A/B* by epigenetic mechanisms. This occurs through interacting with CBX7 (a PRC1 component) and SUZ12 (a PRC2 component) to induce gene silencing at the INK4b-ARF-INK4a locus (66). It also represses tumor suppressor p15. ANRIL is overexpressed in a variety of cancers including leukemia, breast cancer, and prostate cancer where *CDKN2A/B* shows opposite patterns of expression (79).

#### Lung Cancer

Lung cancer is the leading cause of cancer-related deaths and the second most common cancer in both men and women. Deaths caused by lung cancer exceed those of prostate, breast, and colon

cancer combined. lncRNAs implicated in lung cancer include MALAT1, NEAT1, SPRY4-IT1, ANRIL, HNF1A-AS1, UCA1, HOTAIR, GAS5, MEG3, CCAT1, MVIH, H19, CCAT2, AK126698, SOX2-OT, PVT1, EVADR, PANDAR, BANC1, TUG1, and others (Fig. 1; Table 1; refs. 80–82).

#### MALAT1

MALAT1 [metastasis associated lung adenocarcinoma transcript; a.k.a. NEAT2 (nuclear enriched abundant transcript 2)], a 7.5-kb long lncRNA, was originally found to be overexpressed in primary non-small cell lung cancers (83–91). MALAT1 is expressed in many tissues and is evolutionarily conserved among mammals. MALAT1 undergoes posttranscriptional processing to produce a short RNA (cytoplasmic mscRNA, MALAT1-associated small cytoplasmic RNA) and a long MALAT1 transcript that are localized to nuclear speckles and influence the level of phosphorylated splicing-associated serine arginine (SR) proteins. MALAT1 is also overexpressed in other cancers including bladder carcinoma, breast cancer, prostate cancer, and ovarian cancer, and is a potential biomarker and therapeutic target (85, 91). Genome-wide analyses identified multiple mutations in the SRSF1-binding sites of MALAT1 in breast cancer, suggesting an alternation in the splicing pattern in these cancers (91).

Similar to NEAT2, NEAT1 transcripts are also associated with nuclear paraspeckles and are involved in transcriptional and posttranscriptional regulation of the expression of genes such as *ADARB2* (adenosine deaminase, RNA-specific B2; refs. 92–96). NEAT1 has two isoforms: a 3.7 kb (NEAT-1-1) and a 23 kb (NEAT-1-2) long isoform that are widely expressed in several tissues and overexpressed in breast cancer and acute myeloid leukemia. NEAT1 knockdown affects the viability and morphology of Burkitt's lymphoma cells (97).

## Colorectal Cancer

Colorectal cancer is currently the third most common malignancy worldwide. LncRNAs associated with colorectal cancer include *CCAT1*, *CCAT2*, *CCAT1-L*, *CRNDE*, *E2F4*, *HOTAIR*, *HULC*, *MALAT1*, *H19*, *FER1L4*, *PTENP1*, *KCNQ1OT1*, T-UCRs, *ZFAS1*, *OCC-1*, *CCAT1-L*, and others (Fig. 1; Table 1; refs. 89, 98, 99).

### H19

*H19* (2.7 kb) is one of the first lncRNAs discovered and a pivotal player in embryonic development and tumorigenesis (1, 100–116). It is a maternally expressed and paternally imprinted gene located near the telomeric region of chromosome 11p15.5 adjacent to *IGF2* (insulin like growth factor 2) gene. *H19* is conserved between rodents and humans. miR-675, a highly conserved miRNA that regulates a variety of transcripts, resides within exon-1 of the *H19* gene (103). *H19* acts as a decoy for miRNAs, modulating their availability and activity. It interacts with transcription repressors, such as *EZH2* and *MBD1* (methyl-CpG-binding domain protein 1), and induces repression by recruiting to target genes (including *H19*'s reciprocally imprinted gene *IGF2*; ref. 103). *H19* is an oncogenic RNA associated with tumorigenesis starting from the early stages to metastasis (100, 101, 106, 114, 117, 118). Tumor suppressor *p53* and *H19* are mutually counter-regulated (59). *p53* represses the *H19* gene and the *H19*-derived miR-675 inhibits *p53* and *p53*-dependent protein expression (115). The *p53*–*H19* interplay appears to play major roles in tumorigenesis and metastasis (101, 102). *H19* expression is induced by hypoxic stress and linked with epithelial-to-mesenchymal transition (EMT), and its overexpression leads to the activation of genes involved in angiogenesis, cell survival, and proliferation, triggering malignancies such as liver, breast, colorectal, esophageal, lung, pancreatic, gastric, bladder, and cervical carcinomas (100, 101, 107).

### KCNQ1OT1

*KCNQ1OT1* (*KCNQ1* overlapping transcript 1) is a 91-kb nuclear antisense lncRNA that is imprinted from the paternal allele and originates from intron 11 of the *KCNQ1* gene (potassium voltage-gated channel subfamily Q member 1; refs. 119–124). The *KCNQ1OT1* domain is regulated by a functionally independent imprinting control region (ICR) located in an intron of *KCNQ1* (124). The promoter of the *KCNQ1OT1* gene, located within the ICR locus, undergoes methylation on the maternally inherited chromosome and demethylation on the paternally inherited chromosome. Therefore, it preferentially allows the *KCNQ1OT1* gene expression from the paternal allele (122, 124). It interacts with chromatin-modifying enzymes like *PRC1*, *PRC2*, and *G9a* and regulates the silencing of *KCNQ1* via induction of histone and DNA methylation (122, 124). The aberration in *KCNQ1OT1* is associated with Beckwith–Wiede-

mann syndrome, and colorectal, hepatocellular, and pediatric adrenocortical tumors (124, 125).

### T-UCRs

T-UCR lncRNAs are about 200 to 779 nt in length and are generated from ultraconserved regions (UCR) and show tissue-specific expression patterns (126, 127). T-UCR lncRNAs are altered in a variety of cancers including colorectal carcinoma, chronic lymphocytic leukemia, neuroblastomas, hepatocellular carcinoma, and prostate cancer (127). They play a key role in the suppression of miRNAs such as miR-596 and miR-193b involved in carcinogenesis and apoptosis, respectively (128–131). Modulation of T-UCR expression promotes colorectal carcinoma progression (4, 7, 132). Notably, the CpG island hypermethylation-induced epigenetic silencing of tumor suppressor miRNAs appears to be closely associated with a variety of cancers. Recent studies also demonstrate that in addition to miRNAs, various lncRNAs, such as T-UCRs, are silenced via CpG island hypermethylation, which is a common feature of many tumor types (132, 133). Furthermore, the CpG island methylation-induced silencing of protein coding and noncoding sequences in the sense strand as well as antisense-transcripts (many antisense lncRNA) is closely associated with human tumors. For example, antisense lncRNA *VIM-AS1* (vimentin antisense 1), which is regulated via R-loop (three-stranded RNA-DNA hybrid) formation, is silenced in colorectal cancer through CpG island hypermethylation (134).

### CCAT1

*CCAT1* (colon cancer-associated transcript-1; a.k.a. CARLo-5) is an oncogenic lncRNA located at 8q24.21. *CCAT1* expression is induced by c-Myc that binds to its promoter. *CCAT1* epigenetically downregulates c-Myc by acting as a competing endogenous RNA (ceRNA) for miR-155 that represses c-Myc expression. It is also involved in the regulation of *HOXB13* and *SPRY4* (135–137). *CCAT1* has been implicated in acute myeloid leukemia (AML), colorectal, esophageal, lung, and other cancers (138).

## Liver Cancer

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths with an incidence that has tripled since 1980. Although many lncRNAs are implicated in HCC, the most studied are *MALAT1*, *HULC*, *HEIH*, and *HOTAIR* that are known to be upregulated in HCC (47, 139). Other lncRNAs implicated in liver cancer are *linc00152*, *HEIH*, *HOTTIP*, *DILC*, *ZFAS1*, *LET*, *MVIH*, *PCNA-AS1*, *TUC338*, *lncTCF7*, *CCAT1*, *MEG3*, *CUDR*, *LALR1*, and others (Fig. 1; Table 1; ref. 140).

### HULC

*HULC* (highly upregulated in liver cancer), a 1.6-kb oncogenic lncRNA, is overexpressed in HCC (89, 141, 142). Augmented levels of the *HULC* transcript are observed in metastatic liver nodules from colon cancer. *HULC* is upregulated in both tumors and plasma of HCC patients, and is a potential biomarker for HCC. The SNP in *HULC* is associated with HCC susceptibility in hepatitis B virus carriers (143). *HULC* might function to downregulate the activity of miR-372 by acting as an endogenous sponge (144). Suppression of miR-372 by *HULC* represses the translational inhibition of miR-372 target genes. *HULC* promoter possesses a binding site for transcription factor cAMP response



element binding (CREB) and its expression is potentially regulated by CREB phosphorylation (144).

### HEIH

HEIH (high expression in HCC), a 1.6-kb SP1-regulated long lncRNA located in the 5q34.3 locus, is differentially expressed in HCC, closely associated with HCC recurrence, and a prognostic factor for HCC (139, 145, 146). HEIH interacts with EZH2 and regulates EZH2 target genes including cell-cycle-regulatory genes p15, p16, p21, and p57 (145). Knockdown of HEIH reduces cell proliferation and suppresses tumor growth (145).

Other lncRNAs implicated in liver cancer are DILC, H19, TCF7, HOTTIP, and ZFAS1 (139, 147). DILC (downregulated in liver cancer) is a tumor suppressor whose expression is inversely related to those of EpCAM (epithelial cell adhesion molecule), CD24, and CD90 in hepatoma spheroids (148). HOTTIP (HOXA Transcript at the distal Tip) upregulation is associated with liver cancer metastasis (149, 150). HOTTIP, in conjunction with the WDR5/MLL complex, mediates the trimethylation of H3K4 and HOXA gene expression (139, 151, 152).

## Bladder Cancer

Bladder cancer is the tenth most common malignancy in women and the fourth most common in men. lncRNAs implicated in bladder cancer are UCA1, UCA1a, HOXD-AS1, TUG1, ncRAN, GHET1, MALAT1, MEG3, H19, linc-UBC1, lincRNA-p21, SPRY4-IT1, and others (Fig. 1; Table 1; refs. 153–155).

### UCA1

UCA1 (urothelial cancer associated-1), transcribed from 19p13.12, was originally cloned from the human bladder cell line, and is overexpressed in embryonic tissues, bladder cancers, and other cancers (156–158). It promotes chemoresistance through promoting the expression of wingless-type MMTV integration site family member 6 (Wnt6; ref. 157). It also plays a role in  $\beta$ -catenin translocation into the nucleus and TCF7 regulation via interaction with SWI/SNF (switch/sucrose nonfermentable) in other types of cancer (159). UCA1 is a potential urine biomarker for noninvasive diagnosis of bladder cancer. MALAT1 associates with SUZ12 and regulates N-cadherin and E-cadherin expression, promotes tumor growth and metastasis, and forms a fusion gene in renal carcinoma (153).

## Leukemia

Defects in hematopoietic stem cell differentiation and proliferation cause leukemia. A variety of lncRNAs are implicated in leukemia that include CRNDE, HOTAIRM1, DLEU1, DLEU2, LUNAR1, BGL3, MALAT1, CCAT1, CCDC26, BGL3, NEAT1, NALT, UCA1, and others (Fig. 1; Table 1; refs. 160, 161). lncRNA mutations such as internal tandem duplications in the FLT3 (FMS-like tyrosine kinase 3) gene (FLT3-ITD) and mutations in the *NPM1*, *CEBPA*, *IDH2*, *ASXL1*, and *RUNX1* genes are also linked to recurrent leukemia (162, 163).

### DLEU1 and DLEU2

lncRNAs DLEU1 and DLEU2 (deleted in lymphocytic leukemia 1 and 2), originating from the 13q14.3 region, are often deleted in solid tumors and hematopoietic malignancies like chronic lymphocytic leukemia (CLL) and lymphomas (164). DLEU1 and DLEU2 regulate NF- $\kappa$ B activity by regulating genes

that affect NF- $\kappa$ B activity. The promoter regions of DLEU1 and DLEU2 exhibit demethylation or activation marks in CLL (164). DLEU2 acts as a precursor for various miRNAs such as miR-15a and miR-16-1 that are involved in CLL (165).

### LUNAR1

LUNAR1 (leukemia-induced noncoding activator RNA-1), derived from 15q26.3, is a NOTCH-regulated oncogenic lncRNA in T-cell acute lymphoblastic leukemia (T-ALL), and it promotes T-ALL cell growth by enhancing IGF1R expression and IGF1 signaling. LUNAR1 recruits the mediator complex on the IGF1R promoter and regulates its transcription. Abnormal NOTCH1 signaling is closely associated with human T-ALL (166, 167).

### BGL3

BGL3 (beta globin locus transcript 3) is a 3.6-kb lncRNA derived from chromosome 11p15.4. BGL3 expression in leukemic cells is negatively regulated by Bcr-Abl through c-Myc-mediated DNA methylation (168). Conversely, BGL3 regulates Bcr-Abl through sequestering miR-17, miR-93, miR-20a, miR-20b, miR-106a, and miR-106b (168). These miRNAs are known to repress the expression of PTEN (169).

### HOTAIRM1

HOTAIRM1 (HOTAIR myeloid-specific 1), a 483-bp lncRNA transcribed from the HOXA cluster, is expressed in the myeloid lineage. Inhibition of HOTAIRM1 downregulates numerous HOXA genes critical for hematopoiesis (170–172). HOTAIRM1 has a similar expression pattern as that of HOXA1 and HOXA2 in thymus, muscle, colon, lung, kidney, spleen, etc. (173). HOTAIRM1 is induced by all-trans retinoic acid (RA) and is involved in RA-induced myeloid differentiation. HOTAIRM1 regulates myeloid differentiation genes CD11b and CD18, and also interacts with chromatin-modifying enzymes including PRC1, PRC2, and CBX1 (172).

### XIST

XIST (X-inactive specific transcript) induces X-inactivation and is aberrantly expressed in leukemia (162). Homozygous and heterozygous deletion of XIST in hematopoietic stem cells leads to the development of blood cancers, suggesting that aberrant X inactivation promotes carcinogenesis (162). It regulates genes in various other cancers via interaction with PRC1, PRC2, YY1, and CTCF, among others (128, 147, 174, 175). UCA1 knockdown negatively affects the proliferation of AML cells *in vitro* (147, 176).

## Other Cancers

A large number of lncRNAs are identified in various other types of cancers; however, their detailed functions and specificity remain elusive (Fig. 1; Tables 1 and 2; ref. 7). For example, pancreatic cancer, which accounts for 7% of cancer-related deaths worldwide, is associated with lncRNAs H19, HOTAIR, HOTTIP, MALAT1, GAS5, HULC, PVT1, linc-RoR, AF339813, AFAP1-AS, and others (177–181). Ovarian cancer, being the fifth deadliest cancer in women, is associated with abnormal expression of lncRNAs, such as H19, LSINCT-5, HOST2, NEAT1, HOTAIR, PVT1, CDKN2B-AS, CCAT2, UCA1, MEG3, and others (182–184). The lncRNAs implicated in renal cancer include PVT1, LET, PANDAR, PTENP1, HOTAIR, NBAT1, linc00963,



KCNQ1OT1, GAS5, CADM-AS1, RCCRT1, MEG3, SPRY4-IT1, HIF1A-AS, MALAT1, and others (185–187). The lncRNAs implicated in gastric cancer include UCA1, H19, GHET1, CCAT1, linc00152, LSINCT-5, PTENP1, TUG1, MRUL, HOTAIR, MALAT1, GACAT2, FER1L4, MEG3, HULC, PVT1, ANRIL, GAS5, and others (188–191). The expression of lncRNAs H19, MALAT1, CRNDE, ADAMTS9-AS2, DISC2, MEG3, CASC2, TSLC1-AS1, and POU3F3 is positively correlated with malignant glioma (192, 193). MEG3 is a tumor suppressor lncRNA that is highly expressed in normal brain tissue and downregulated in gliomas (194). FER1L4 (Fer-1-like protein 4) is a tumor suppressor lncRNA involved in the regulation of PTEN and inhibition of Akt phosphorylation in endometrial cancer (195). NBAT1 (neuroblastoma-associated transcript 1) represses the expression of neuronal-specific transcription factor NRSF/REST through association with PRC2 (196, 197).

GAS5 (growth arrest specific 5) and SRA (steroid receptor RNA activator) are two lncRNAs implicated in hormone signaling (198–201). GAS5 produces two splice variant lncRNAs, and its introns also give rise to several snoRNAs (small nucleolar RNA) involved in the biosynthesis of ribosomal RNA from its introns. GAS5 interacts with glucocorticoid receptor (GR) and suppresses the expression of GR-regulated genes (202). It causes growth arrest and apoptosis and induces PTEN via inhibiting miR-103 (198). GAS5 acts as a tumor suppressor and its misregulation and genetic aberrations are associated with breast cancer, prostate cancer, leukemia, gastric cancer, and others (203). The lncRNA SRA interacts with various steroid hormone receptors and stimulates transcriptional activation, and is associated with breast, uterine, ovarian, and prostate cancers (204).

#### TERRA

TERRA (telomeric repeat-containing RNA) is a set of lncRNAs (ranging in size from 100 bp to 9 kb) transcribed from telomeres. LncRNAs containing UUAGGG repeats are generally called TERRA (205–208). TERRA interacts with telomere-associated TRF1 and TRF2 (telomere repeat factors 1 and 2), subunits of the origin recognition complex (ORC), heterochromatin protein 1 (HP1), H3K9-methylated histone, and facilitates heterochromatin formation at telomeres. TERRA is known to negatively regulate telomerase and act as a tumor suppressor (207, 208).

#### ZFAS1

ZFAS1 (ZNF1 antisense RNA 1) is a spliced and polyadenylated lncRNA transcribed from the 5' end of *ZNF1*. It is derived from chromosome 20q13.13, and is implicated in different types of cancer including gastric cancer, colorectal cancer, and hepatocellular cancer, among others. It interacts with CDK1 and cyclin B to control p53-dependent cell-cycle regulation (209). In addition, it promotes cell proliferation by recruiting EZH2 and LSD1/CoREST to the promoters of genes including KLF2 (Kruppel like factor 2) and NKD2 (naked cuticle 2) to regulate their expression (210). It also acts as a sponge for tumor suppressor miR-150 (211). Knockdown of ZFAS1 results in the repression of cell proliferation, migration, and colony formation (210, 212).

#### PVT1

PVT1 (plasmacytoma variant translocation 1) is an oncogenic, intergenic lncRNA derived from 8q24.21 with multiple splice isoforms (213–215). It is upregulated in different types of cancer such as ovarian cancer, cervical cancer, and pancreatic cancer,

among others. It suppresses the phosphorylation of Myc, thereby enhancing its stability (216). Furthermore, it promotes proliferation via interaction with NOP2 (nucleolar protein 2 homolog) with the help of TGF $\beta$  (213). PVT1 promotes cell proliferation and invasion in gastric cancer by recruiting EZH2 to repress the expression of tumor suppressor genes p15 and p16 (214). It associates with a multifunctional DNA- and RNA-binding protein called nucleolin involved in oncogene expression and ribosomal biogenesis, among other activities (217).

#### MEG3

MEG3 (maternally expressed 3) is an imprinted, tumor-suppressive lncRNA transcribed from chromosome 14q32.2 (218–221). It is a polyadenylated lncRNA overexpressed in human pituitary, but downregulated in cancer cells (219). Overexpression of MEG3 in bladder cancer cells has been shown to induce autophagy and increase cell proliferation (222). MEG3 is involved in the accumulation of tumor suppressor p53 and regulation of TGF- $\beta$  pathway genes involved in cell invasion, immune regulation, etc. It also interacts with PRC2 to repress MDM2 (murine double minute 2), which contributes to p53 accumulation (221, 223).

## LncRNAs as Biomarkers and in Gene Therapy

Numerous lncRNAs are aberrantly expressed in various tumors and some appear to be cancer-specific. Many lncRNAs (or their processed fragments) are stable in body fluids and detectable in the plasma and urine of cancer patients (24, 224). Their levels are indicative of the severity of the disease. All these factors render lncRNAs an attractive choice for their applications as noninvasive biomarkers and therapeutic targets for the treatment of cancer (Table 2; refs. 28, 30, 92, 143, 212, 225–254). LncRNAs differ from protein-coding genes in many respects. First, due to their greater abundance than protein-coding genes, a modulation in larger number of lncRNA expression may be observed in a given subtype of cancer, which provides a larger window for the detection of subtype-specific lncRNA-based biomarker. Subtype/tissue-specific lncRNA expressions are crucial for developing novel diagnostic biomarker and personalized therapy (43, 245). LncRNAs, being large in size, may fold into complex secondary/tertiary structures and scaffolds through which they may interact with various proteins, transcriptional regulators, mRNA (complementary), and DNA sequences, which may aid in cancer initiation and progression. The presence of a large number of regulatory interaction sites in lncRNAs provides a wider platform for developing novel structure-based cancer drugs. Furthermore, given their participation in diverse cell signaling pathways and tissue-specific expression, lncRNAs can be utilized to formulate novel strategies for specific cancer subtype diagnosis and targeting (255, 256).

Few lncRNAs are already implicated as biomarkers and some of them are in clinical trials (Table 2; refs. 230, 257). For example, lncRNA PCA3, which is highly upregulated and specific to prostate cancer, is detectable in urine with levels that correspond to the severity of prostate cancer (30, 31, 225). As it can be detected in urine, PCA3 has advantages over the widely used serum-based prostate cancer biomarker PSA (prostate-specific antigen) for noninvasive diagnosis of prostate cancer (258). In addition, PCAT-1, PRNCR1, PCGEM, PlncRNA1, and PCAT-18 are highly

expressed in prostate tumors and are potential diagnostic markers (Table 2; refs. 44, 259). Circulating HOTAIR may also be used to diagnose breast cancer (228). ZFAS1, HIF1a-AS2, and others are also implicated as biomarkers for breast cancer (Table 2). Similarly, MALAT1, UCA1, ANRIL, and NEAT1 can be used to predict early stage as well as metastatic lung cancers (Table 2; ref. 85). The expression of HOTAIR, CCAT1, FER1L4, and others is linked to colorectal cancer (Table 2). CpG-island methylation of T-UCR promoter is also linked to colorectal cancer diagnosis. lncRNAs H19, HULC, HEIH, linc00152, and MVIH are highly upregulated in hepatocellular cancer (HCC) and are valuable HCC biomarkers (Table 2; ref. 260). HULC expression correlates with histologic grade and oncoprotein hepatitis B virus X (HBx; ref. 261). Hepatitis B virus (HBV)-positive hepatocellular cancer can be detected using lncRNAs uc001ncr and AX800134. Uc001ncr and AX800134 have a 100% detection rate in HCC patients (143). HOTAIR overexpression may be used to predict the recurrence of HCC and is highly expressed in 65.7% of recurrence HCC patients (47, 262). UCA1, H19, and HOTAIR expression may be used as a biomarker to detect bladder cancer (Table 2; ref. 176). CRNDE is expressed in the APL (acute promyelocytic leukemia) subtype of AML ten times more than the other subtypes. This makes CRNDE a suitable biomarker to detect the APL subtype of AML (245). LET, PVT1, PANDAR, and PTENP1 expression is linked to renal cancer (Table 2). Thus, lncRNAs appear to be promising novel diagnostic and prognostic markers for a variety of cancers (Table 2); however, there are still many challenges and validations required for their clinical applications.

As lncRNA expressions are differentially modulated in different types of cancer and their expression levels correlate with tumorigenesis, tumor aggressiveness, and stages, they are potential targets for cancer therapy. There are several ways by which lncRNAs may be targeted to modulate their expression: (i) lncRNA transcript degradation/destabilization by using lncRNA-specific siRNAs, antisense oligonucleotide (ASO), gapmers, and ribozymes; (ii) modulating lncRNA transcription by altering the lncRNA-coded promoter activity (e.g., via inhibition of transcription factors binding to respective promoters); (iii) blocking interactions between lncRNAs and regulatory factors—small synthetic molecules/peptides can be developed that are designed to block the binding of lncRNAs with protein, DNA, RNA, or other interacting complexes by associating with specific binding pockets; and (iv) functional disruption of lncRNAs using aptamers that can be selected to bind at specific structural regions to target lncRNAs and antagonize their association with their binding partners (263, 264). For example, siRNA-mediated downregulation of HOTAIR expression leads to reduced tumor cell viability and invasiveness and induction of apoptosis in breast tumors (228). CCAT2 is upregulated in colorectal cancer and has been targeted by specific miRNAs to suppress colorectal cancer growth (265–267). Antisense-mediated silencing of MALAT1 prevents *in vivo* lung cancer metastasis (85). Breast cancer progression can be hindered through systemic knockdown of MALAT1 using antisense oligonucleotide (85, 91, 201). Antisense-mediated lncRNA targeting has shown to be promising in the treatment of other disorders like Angelman's syndrome through silencing lncRNA UBE3A-AS (268, 269). Oncogenic lncRNA H19 is overexpressed in a variety of cancers such as pancreatic tumors. The H19 promoter has been used to express diphtheria toxin (DTA) in pancreatic cancer cells (117, 118, 270). Administration of pancreatic tumors with a H19-DTA plasmid construct resulted

in a significant decrease in tumor size and metastasis. The H19 (and IGF2) regulatory sequences can be used to inhibit the growth and metastasis of colorectal cancer. Overall, lncRNA-based targeted cancer therapies are promising; however, at present, they are at their infancy and require further development of experimental strategies, siRNA/antisense delivery strategies, screening novel small-molecule libraries, and many clinical trials prior to their success in targeted, lncRNA-based gene therapy.

Apart from evaluating the direct significance of lncRNAs in cancer diagnosis and therapy, they can also be considered for improving therapeutic efficacy and development of combination therapy. Therapeutic resistance (such as chemo- or radioresistance) is a major challenge in cancer treatment; however, this could be improved by increasing the therapeutic sensitivity of tumors by modulating a critical cell signaling pathway that confers resistance. As lncRNAs are closely associated with many cell signaling processes, the modulation of their expression could be done to improve the therapeutic sensitivity of tumors. One approach is to resensitize chemoresistant cells by modulating factors associated with DNA damage response pathways. For example, knockdown of HOTAIR enhances the sensitivity of cancer cells to chemotherapeutic agents like cisplatin and doxorubicin (271–273). Cisplatin-mediated upregulation of HOTAIR in human lung adenocarcinoma cells suppressed p21 (WAF1/CIP1) signaling pathway and caused a G<sub>0</sub>–G<sub>1</sub> arrest by modulating the p53 expression and HOXA1 methylation (157, 274). lncRNA TUG1 (taurine upregulated gene 1; refs. 2, 3, 275–277) overexpression is responsible for the chemoresistance of lung cancer cells. TUG1 regulates the expression of LIM-kinase 2b and other cell-cycle-associated genes through recruiting EZH2 to its promoter. TUG1 knockdown has been shown to enhance chemosensitivity in lung cancer (278). Silencing CRNDE results in the suppression of cell proliferation and chemoresistance in colorectal cancer. CRNDE inhibits the expression of miR-181a-5p, which in turn silences Wnt/ $\beta$ -catenin signaling (279). Similarly, HOTTIP promotes chemoresistance via activation of Wnt/ $\beta$ -catenin signaling (280). GAS5 modulates chemoresistance in gastric cancer by acting as a sponge for miR-23a that inhibits the expression of metallothionein 2A (MT2A; ref. 281). In a similar role, CCAT1 sponges let-7c-mediated release of Bcl-xL. This involves EMT and resistance to docetaxel (136). MALAT1 knockdown causes resensitization of glioblastoma multiforme cells to temozolomide. The MALAT1-mediated chemoresistance in glioblastoma multiforme cells is made possible via inhibition of miR-203, thereby activating the expression of thymidylate synthase (282). Other lncRNAs that may be targeted to increase the chemosensitivity of tumors include HULC (gastric cancer), H19 (breast cancer), ODRUL (osteosarcoma), OMRUL (lung cancer), and PVT1 (pancreatic cancer; refs. 216, 283–285). Thus, it is evident that the modulation of lncRNA expression can be exploited to improve the therapeutic sensitivity of tumors and may also be used for combination therapy.

## Conclusions

lncRNAs are emerging stars in cancer, diagnosis, and therapy (286). The discovery of huge numbers of lncRNA, their wide range of expression patterns in various types of cancer, their tumor specificity, and their stability in circulating body fluids (plasma and urine) provide a new foundation for developing diagnosis and therapies for cancer. lncRNA expression may also be used to

predict the cancer prognosis and patients outcome. LncRNAs are major regulators of chromatin dynamics and gene regulation, associated with a variety of cell signaling pathways, and their expressions are influenced by a variety of factors including hormones, nutrients, age, and sex (162, 287–290). Aberrant expression, mutations and SNPs of lncRNAs are associated with tumorigenesis and metastasis. Some lncRNAs act as oncogenes, whereas others act as tumor suppressors (291). Oncogenic lncRNAs include PCA3, PCGEM1, PCAT1, PCAT18, CTBP-AS, SCHLAP1, HOTAIR, ANRIL, MALAT1, NEAT1, H19, KCNQ1OT1, lncTCF-7, HOTTIP, HULC, HEIH, TUG1, UCA1, PVT1, and LSINCT5 (286). Tumor suppressor lncRNAs include GAS5, MEG3, DILC, NBAT-1, DLEU1, DLEU2, TERRA, BGL3, and others. Novel lncRNAs are still being discovered (292). Thus, lncRNAs holds strong promise towards the discovery of novel diagnostics and therapeutics for cancer. However, there are still many challenges. First, given the large number of lncRNAs and their up- or downregulation in various cancers, it is crucial to identify the most important lncRNAs associated with a specific types/subtype of cancer. Second, the field of lncRNAs is at its infancy at this point; the structural and functional information on most lncRNAs remain uncharacterized. Without detailed understanding on the structure and functions of lncRNAs, developing lncRNA-based therapies is like "shooting in the dark". In addition, unlike protein-coding genes, lncRNAs are poorly conserved across different species; therefore, the structural and functional information as well as the promising therapeutic strategies developed using *in vitro* and animal models may not be easily extended to immediate human application and may need detailed clinical studies. To fully explore the potential of lncRNAs in cancer diagnosis and targeted therapy, it is important to characterize each lncRNA in detail, identify their cellular functions, roles in diseases, and SNPs. The cause–effect relationships of each lncRNA need to be

established for determining their tissue specificity and linking them to tumor stage. The future studies on the use of lncRNAs as biomarkers and therapeutics should focus not only on their identification and functional characterization, but also on optimizing isolation procedures, characterizing variations by internal and external factors using large numbers of statistically significant patient cohorts, and development of proper animal models for testing and validations, prior to clinical trials. Development of technologies for efficient detection of lncRNAs and their tissue-specific delivery methods are critical to the success of the diagnostics and therapeutics. Recent advancements in CRISPR/Cas9 technologies for gene knockout, knock-in, and point mutations may facilitate understanding the biological roles of lncRNAs and aid in the development of lncRNA-based targeted cancer therapy. Nevertheless, discovering novel lncRNAs, identifying their function and association with various cancer subtypes, developing novel lncRNA-based strategies for diagnosis and targeted therapies appear very promising, bring a new paradigm in cancer research, and may emerge as a major therapeutic strategy for the treatment of cancer in the near future.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### Acknowledgments

We thank Mandal lab members for helpful discussions. We sincerely apologize to all the colleagues whose contributions are not cited here due to the limitation in the scope and length of the article.

#### Grant Support

This work was supported by NIH grant 1R15 ES019129-01.

Received September 26, 2016; revised April 5, 2017; accepted May 4, 2017; published OnlineFirst July 12, 2017.

#### References

- Glassman ML, de Groot N, Hochberg A. Relaxation of imprinting in carcinogenesis. *Cancer Genet Cytogenet* 1996;89:69–73.
- Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proc Natl Acad Sci U S A* 2009;106:11667–72.
- Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature* 2009;458:223–7.
- Bhan A, Mandal SS. LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer. *Biochim Biophys Acta* 2015;1856:151–64.
- Sanfilippo PG, Hewitt AW. Translating the ENCYClopedia Of DNA Elements Project findings to the clinic: ENCODE's implications for eye disease. *Clin Exp Ophthalmol* 2014;42:78–83.
- Tragante V, Moore JH, Asselbergs FW. The ENCODE project and perspectives on pathways. *Genet Epidemiol* 2014;38:275–80.
- Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. *ChemMedChem* 2014;9:1932–56.
- Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. *RNA Biol* 2013;10:925–33.
- Wang Kevin C, Chang Howard Y. Molecular Mechanisms of Long Non-coding RNAs. *Mol Cell* 2011;43:904–14.
- Pontier DB, Gribnau J. Xist regulation and function explored. *Hum Genet* 2011;130:223–36.
- Dong Y, He D, Peng Z, Peng W, Shi W, Wang J, et al. Circular RNAs in cancer: an emerging key player. *J Hematol Oncol* 2017;10:2.
- Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. *Nature* 2013;495:384–8.
- Vicens Q, Westhof E. Biogenesis of Circular RNAs. *Cell* 2014;159:13–4.
- Zhang XO, Dong R, Zhang Y, Zhang JL, Luo Z, Zhang J, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. *Genome Res* 2016;26:1277–87.
- Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. *Cancer Res* 2013;73:5609–12.
- Wang Y, Mo Y, Gong Z, Yang X, Yang M, Zhang S, et al. Circular RNAs in human cancer. *Mol Cancer* 2017;16:25.
- Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. *Nat Biotechnol* 2014;32:453–61.
- Salzman J. Circular RNA expression: its potential regulation and function. *Trends Genet* 2016;32:309–16.
- Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. *PLoS Genet* 2010;6:e1001233.
- Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, et al. Circular intronic long noncoding RNAs. *Mol Cell* 2013;51:792–806.
- Vitiello M, Tuccoli A, Poliseno L. Long non-coding RNAs in cancer: implications for personalized therapy. *Cell Oncol* 2015;38:17–28.
- Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. *Mol Cancer* 2016;15:43.
- Kornfeld JW, Bruning JC. Regulation of metabolism by long, non-coding RNAs. *Front Genet* 2014;5:57.

24. Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. *Dis Markers* 2016;2016: 9085195.
25. Brunner AL, Beck AH, Edris B, Sweeney RT, Zhu SX, Li R, et al. Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. *Genome Biol* 2012;13: R75.
26. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, et al. Comprehensive genomic characterization of long non-coding RNAs across human cancers. *Cancer Cell* 2015;28:529–40.
27. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. *Nat Biotechnol* 2011;29:742–9.
28. Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. *Oncotarget* 2014;5:764–74.
29. Warrick JI, Tomlins SA, Carskadon SL, Young AM, Siddiqui J, Wei JT, et al. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization—a correlative study with urine PCA3 and TMPRSS2-ERG. *Mod Pathol* 2014;27:609–20.
30. Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A, et al. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. *J Urol* 2014;191:1743–8.
31. Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, et al. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. *Eur Urol* 2014;66: 1109–15.
32. Albino G, Capoluongo E, Rocchetti S, Palumbo S, Zuppi C, Cirillo-Marucco E. Evaluation of the diagnostic and predictive power of PCA3 in the prostate cancer. A different best cut-off in each different scenario. Preliminary results. *Arch Ital Urol Androl* 2014;86:306–10.
33. Dijkstra S, Leyten GH, Jannink SA, de Jong H, Mulders PF, van Oort IM, et al. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. *Prostate* 2014;74: 1222–30.
34. Salameh A, Lee AK, Cardo-Vila M, Nunes DN, Efstathiou E, Staquicini FI, et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. *Proc Natl Acad Sci U S A* 2015;112: 8403–8.
35. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. *Nature* 2013;500:598–602.
36. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. *DNA Cell Biol* 2006;25:135–41.
37. Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics G, et al. A long noncoding RNA connects c-Myc to tumor metabolism. *Proc Natl Acad Sci U S A* 2014;111:18697–702.
38. Walsh AL, Tuzova AV, Bolton EM, Lynch TH, Perry AS. Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'? *Trends Mol Med* 2014;20:428–36.
39. Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. *Neoplasia* 2014;16:900–8.
40. Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, et al. Role of transcriptional corepressor CtBP1 in prostate cancer progression. *Neoplasia* 2012;14:905–14.
41. Weichenhan D, Plass C. The evolving epigenome. *Hum Mol Genet* 2013; 22:R1–6.
42. Moiola CP, De Luca P, Zalazar F, Cotignola J, Rodriguez-Segui SA, Gardner K, et al. Prostate tumor growth is impaired by CtBP1 depletion in high-fat diet-fed mice. *Clin Cancer Res* 2014;20:4086–95.
43. Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, et al. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. *Oncotarget* 2014;5:9864–76.
44. Li Y, Wang X. Role of long noncoding RNAs in malignant disease (Review). *Mol Med Rep* 2016;13:1463–9.
45. Bhan A, Hussain I, Ansari KI, Kasiri S, Bashyal A, Mandal SS. Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. *J Mol Biol* 2013;425:3707–22.
46. Cui L, Xie XY, Wang H, Chen XL, Liu SL, Hu LN. [Expression of long non-coding RNA HOTAIR mRNA in ovarian cancer]. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2013;44:57–9.
47. Geng Y, Xie S, Li Q, Ma J, Wang G. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. *J Int Med Res* 2011;39:2119–28.
48. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. *Oncogene* 2013;32:1616–25.
49. Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J, et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. *Am J Pathol* 2013;182:64–70.
50. Nakagawa T, Endo H, Yokoyama M, Abe J, Tamai K, Tanaka N, et al. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. *Biochem Biophys Res Commun* 2013;436:319–24.
51. Yang Z, Zhou L, Wu L-M, Lai M-C, Xie H-Y, Zhang F, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. *Ann Surg Oncol* 2011;18:1243–50.
52. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* 2010;464:1071–6.
53. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Bruggmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell* 2007;129:1311–23.
54. Tsai MC, Manor O, Wan Y, Mosammamaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. *Science* 2010;329:689–93.
55. Li L, Liu B, Wapinski OL, Tsai MC, Qu K, Zhang J, et al. Targeted disruption of HotaIR leads to homeotic transformation and gene derepression. *Cell Rep* 2013;5:3–12.
56. Xhemalce B. From histones to RNA: role of methylation in cancer. *Brief Funct Genomics* 2013;12:244–53.
57. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. *Cancer Res* 2011;71:6320–6.
58. Milhem MM, Knutson T, Yang S, Zhu D, Wang X, Leslie KK, et al. Correlation of MTDH/AEG-1 and HOTAIR expression with metastasis and response to treatment in sarcoma patients. *J Cancer Sci Ther* 2011;5: 59.
59. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. *Annu Rev Biochem* 2012;81:145–66.
60. Yoon JH, Abdelmohsen K, Kim J, Yang X, Martindale JL, Tominaga-Yamanaka K, et al. Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination. *Nat Commun* 2013;4:2939.
61. Bhan A, Hussain I, Ansari KI, Bobzean SA, Perrotti LI, Mandal SS. Bisphenol-A and diethylstilbestrol exposure induces the expression of breast cancer associated long noncoding RNA HOTAIR in vitro and in vivo. *J Steroid Biochem Mol Biol* 2014;141:160–70.
62. Bhan A, Mandal SS. Estradiol-induced transcriptional regulation of long non-coding RNA, HOTAIR. *Methods Mol Biol* 2016;1366:395–412.
63. Ansari KI, Hussain I, Das HK, Mandal SS. Overexpression of human histone methylase MLL1 upon exposure to a food contaminant mycotoxin, deoxynivalenol. *FEBS J* 2009;276:3299–307.
64. Ansari KI, Hussain I, Kasiri S, Mandal SS. HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen via involvement of histone methylases MLL3 and MLL4. *J Mol Endocrinol* 2012; 48:61–75.
65. Bhan A, Hussain I, Ansari KI, Bobzean SA, Perrotti LI, Mandal SS. Histone methyltransferase EZH2 is transcriptionally induced by estradiol as well as estrogenic endocrine disruptors bisphenol-A and diethylstilbestrol. *J Mol Biol* 2014;426:3426–41.
66. Aguilo F, Zhou MM, Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. *Cancer Res* 2011;71: 5365–9.
67. Iacobucci I, Sazzini M, Garagnani P, Ferrari A, Boattini A, Lonetti A, et al. A polymorphism in the chromosome 9p21 ANRIL locus is associated to

- Philadelphia positive acute lymphoblastic leukemia. *Leuk Res* 2011;35:1052–9.
68. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. *Oncogene* 2011;30:1956–62.
  69. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. *Mol Cell* 2010;38:662–74.
  70. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. *Nature* 2008;451:202–6.
  71. Healy J, Bélanger H, Beaulieu P, Larivière M, Labuda D, Sinnenet D. Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. *Blood* 2007;109:683–92.
  72. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. *PLoS Genet* 2010;6:e1000899.
  73. Holdt LM, Beutner F, Scholz M, Gielen S, Gäbel G, Bergert H, et al. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. *Arterioscler Thromb Vasc Biol* 2010;30:620–7.
  74. Pasmant E, Sabbagh A, Vidaud M, Bieche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. *FASEB J* 2011;25:444–8.
  75. Schaefer AS, Richter GM, Groessner-Schreiber B, Noack B, Nothnagel M, El Mokhtari NE, et al. Identification of a shared genetic susceptibility locus for coronary heart disease and periodontitis. *PLoS Genet* 2009;5:e1000378.
  76. Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. *Oncol Rep* 2016;36:263–70.
  77. Sun Y, Zheng ZP, Li H, Zhang HQ, Ma FQ. ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro. *Mol Med Rep* 2016;14:1714–20.
  78. Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression clusters with ARF. *Cancer Res* 2007;67:3963–9.
  79. Huarte M. The emerging role of lncRNAs in cancer. *Nat Med* 2015;21:1253–61.
  80. Peng Z, Zhang C, Duan C. Functions and mechanisms of long noncoding RNAs in lung cancer. *Onco Targets Ther* 2016;9:4411–24.
  81. Wu CH, Hsu CL, Lu PC, Lin WC, Juan HF, Huang HC. Identification of lncRNA functions in lung cancer based on associated protein-protein interaction modules. *Sci Rep* 2016;6:35939.
  82. Wei MM, Zhou GB. Long non-coding RNAs and their roles in non-small-cell lung cancer. *Genomics Proteomics Bioinformatics* 2016;14:280–8.
  83. Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, Xuan Z, et al. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. *EMBO J* 2010;29:3082–93.
  84. Guo F, Li Y, Liu Y, Wang J, Li G. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. *Acta Biochim Biophys Sin* 2010;42:224–9.
  85. Gutschner T, Hämmerle M, Eifßmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. *Cancer Res* 2013;73:1180–9.
  86. Han Y, Liu Y, Nie L, Gui Y, Cai Z. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder. *Urology* 2013;81:209.
  87. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. *Oncogene* 2003;22:8031–41.
  88. Lai M-c, Yang Z, Zhou L, Zhu Q-q, Xie H-y, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. *Med Oncol* 2012;29:1810–6.
  89. Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. *Int J Biochem Cell Biol* 2013;45:1895–910.
  90. Xu ZY, Yu QM, Du YA, Yang LT, Dong RZ, Huang L, et al. Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer. *Int J Biol Sci* 2013;9:587–97.
  91. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. *Genes Dev* 2016;30:34–51.
  92. Hu X, Bao J, Wang Z, Zhang Z, Gu P, Tao F, et al. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer. *Tumour Biol* 2016;37:3497–504.
  93. Jiang P, Wu X, Wang X, Huang W, Feng Q. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. *Oncotarget* 2016;7:43337–51.
  94. Sun C, Li S, Zhang F, Xi Y, Wang L, Bi Y, et al. Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. *Oncotarget* 2016;7:51784–814.
  95. Hirose T, Virnicchi G, Tanigawa A, Naganuma T, Li R, Kimura H, et al. NEAT1 long noncoding RNA regulates transcription via protein sequestration within subnuclear bodies. *Mol Biol Cell* 2014;25:169–83.
  96. Ke H, Zhao L, Feng X, Xu H, Zou L, Yang Q, et al. NEAT1 is required for survival of breast cancer cells through FUS and miR-548. *Gene Regul Syst Bio* 2016;10:11–7.
  97. Blume CJ, Hotz-Wagenblatt A, Hullein J, Sellner L, Jethwa A, Stolz T, et al. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. *Leukemia* 2015;29:2015–23.
  98. Xie X, Tang B, Xiao YF, Xie R, Li BS, Dong H, et al. Long non-coding RNAs in colorectal cancer. *Oncotarget* 2016;7:5226–39.
  99. Xu MD, Qi P, Du X. Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. *Mod Pathol* 2014;27:1310–20.
  100. Ariel I, Sughayer M, Fellig Y, Pizov G, Ayesh S, Podeh D, et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. *Mol Pathol* 2000;53:320–3.
  101. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrusil IL, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. *Cancer Res* 2006;66:5330–7.
  102. Berteaux N, Lottin S, Monté D, Pinte S, Quatannens B, Coll J, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. *J Biol Chem* 2005;280:29625–36.
  103. Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. *RNA* 2007;13:313–6.
  104. Castle JC, Armour CD, Lower M, Haynor D, Biery M, Bouzek H, et al. Digital genome-wide ncRNA expression, including SnoRNAs, across 11 human tissues using polyA-neutral amplification. *PLoS One* 2010;5:e11779.
  105. Hashimoto K, Azuma C, Tokugawa Y, Nobunaga T, Aki TA, Matsui Y, et al. Loss of H19 imprinting and up-regulation of H19 and SNRPN in a case with malignant mixed Mullerian tumor of the uterus. *Hum Pathol* 1997;28:862–5.
  106. Hibi K, Nakamura H, Hirai A, Fujikake Y, Kasai Y, Akiyama S, et al. Loss of H19 imprinting in esophageal cancer. *Cancer Res* 1996;56:480–2.
  107. Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. *Oncogene* 1995;10:1193–8.
  108. Lottin S, Adriaenssens E, Dupressoir T, Berteaux N, Montpelliér C, Coll J, et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. *Carcinogenesis* 2002;23:1885–95.
  109. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, et al. The H19 non-coding RNA is essential for human tumor growth. *PLoS One* 2007;2:e845.
  110. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-lail R, Fellig Y, et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. *Biochim Biophys Acta* 2010;1803:443–51.
  111. Pachnis V, Belayew A, Tilghman SM. Locus unlinked to alpha-fetoprotein under the control of the murine raf and Rif genes. *Proc Natl Acad Sci U S A* 1984;81:5523–7.
  112. Pachnis V, Brannan CI, Tilghman SM. The structure and expression of a novel gene activated in early mouse embryogenesis. *EMBO J* 1988;7:673–81.

113. Poirier F, Chan CT, Timmons PM, Robertson EJ, Evans MJ, Rigby PW. The murine H19 gene is activated during embryonic stem cell differentiation in vitro and at the time of implantation in the developing embryo. *Development* 1991;113:1105–14.
114. Takeuchi S, Hofmann W-K, Tsukasaki K, Takeuchi N, Ikezoe T, Matsushita M, et al. Loss of H19 imprinting in adult T-cell leukaemia/lymphoma. *Br J Haematol* 2007;137:380–1.
115. Yoshimizu T, Miroglia A, Ripoché M-A, Gabory A, Vernucci M, Riccio A, et al. The H19 locus acts in vivo as a tumor suppressor. *Proc Natl Acad Sci U S A* 2008;105:12417–22.
116. Brannan CI, Dees EC, Ingram RS, Tilghman SM. The product of the H19 gene may function as an RNA. *Mol Cell Biol* 1990;10:28–36.
117. Amit D, Hochberg A. Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. *Int J Clin Exp Med* 2012;5:296–305.
118. Sorin V, Ohana P, Gallula J, Birman T, Matouk I, Hubert A, et al. H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. *ISRN Oncol* 2012;2012:351750.
119. Mitsuya K, Meguro M, Lee MP, Katoh M, Schulz TC, Kugoh H, et al. LIT1, an imprinted antisense RNA in the human KvLQT1 locus identified by screening for differentially expressed transcripts using monochromosomal hybrids. *Hum Mol Genet* 1999;8:1209–17.
120. Nakano S, Murakami K, Meguro M, Soejima H, Higashimoto K, Urano T, et al. Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers. *Cancer Sci* 2006;97:1147–54.
121. Pandey RR, Ceribelli M, Singh PB, Ericsson J, Mantovani R, Kanduri C. NF-Y regulates the antisense promoter, bidirectional silencing, and differential epigenetic marks of the Kcnq1 imprinting control region. *J Biol Chem* 2004;279:52685–93.
122. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. *Mol Cell* 2008;32:232–46.
123. Zhang H, Zeitz MJ, Wang H, Niu B, Ge S, Li W, et al. Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. *J Cell Biol* 2014;204:61–75.
124. Robbins KM, Chen Z, Wells KD, Rivera RM. Expression of KCNQ1OT1, CDKN1C, H19, and PLAGL1 and the methylation patterns at the KvDMR1 and H19/IGF2 imprinting control regions is conserved between human and bovine. *J Biomed Sci* 2012;19:95.
125. DeBaun MR, Niemitz EL, McNeil DE, Brandenburg SA, Lee MP, Feinberg AP. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. *Am J Hum Genet* 2002;70:604–11.
126. Esteller M. Non-coding RNAs in human disease. *Nat Rev Genet* 2011;12:861–74.
127. Peng JC, Shen J, Ran ZH. Transcribed ultraconserved region in human cancers. *RNA Biol* 2013;10:1771–7.
128. Terreri S, Durso M, Colonna V, Romanelli A, Terracciano D, Ferro M, et al. New cross-talk layer between ultraconserved non-coding RNAs, MicroRNAs and polycomb protein YY1 in bladder cancer. *Genes* 2016;7:pii: E127
129. Wang C, Wang Z, Zhou J, Liu S, Wu C, Huang C, et al. TUC.338 promotes invasion and metastasis in colorectal cancer. *Int J Cancer* 2017;140:1457–64.
130. Jiang BC, Yang T, He LN, Tao YX, Gao YJ. Altered T-UCRs expression profile in the spinal cord of mice with neuropathic pain. *Transl Perioper Pain Med* 2016;1:1–10.
131. Braconi C, Valeri N, Kogure T, Gasparini P, Huang N, Nuovo GJ, et al. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. *Proc Natl Acad Sci U S A* 2011;108:786–91.
132. Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, et al. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. *Oncogene* 2010;29:6390–401.
133. Liz J, Portela A, Soler M, Gomez A, Ling H, Michlewski G, et al. Regulation of pri-miRNA processing by a long noncoding RNA transcribed from an ultraconserved region. *Mol Cell* 2014;55:138–47.
134. Boque-Sastre R, Soler M, Oliveira-Mateos C, Portela A, Moutinho C, Sayols S, et al. Head-to-head antisense transcription and R-loop formation promotes transcriptional activation. *Proc Natl Acad Sci U S A* 2015;112:5785–90.
135. Zhang E, Han L, Yin D, He X, Hong L, Si X, et al. H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. *Nucleic Acids Res* 2016;45:3086–101.
136. Chen J, Zhang K, Song H, Wang R, Chu X, Chen L. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. *Oncotarget* 2016;7:62474–89.
137. Deng L, Yang SB, Xu FF, Zhang JH. Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge. *J Exp Clin Cancer Res* 2015;34:18.
138. Guo X, Hua Y. CCAT1: an oncogenic long noncoding RNA in human cancers. *J Cancer Res Clin Oncol* 2017;143:555–62.
139. He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, et al. Long noncoding RNAs: novel insights into hepatocellular carcinoma. *Cancer Lett* 2014;344:20–7.
140. Parasramka MA, Maji S, Matsuda A, Yan IK, Patel T. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. *Pharmacol Ther* 2016;161:67–78.
141. Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. *Gastroenterology* 2007;132:330–42.
142. Du Y, Kong G, You X, Zhang S, Zhang T, Gao Y, et al. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. *J Biol Chem* 2012;287:26302–11.
143. Wang K, Guo WX, Li N, Gao CF, Shi J, Tang YF, et al. Serum lncRNAs profiles serve as novel potential biomarkers for the diagnosis of HBV-positive hepatocellular carcinoma. *PLoS One* 2015;10:e0144934.
144. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. *Nucleic Acids Res* 2010;38:5366–83.
145. Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. *Hepatology* 2011;54:1679–89.
146. Zhang Y, Li Z, Zhang Y, Zhong Q, Chen Q, Zhang L. Molecular mechanism of HEIH and HULC in the proliferation and invasion of hepatoma cells. *Int J Clin Exp Med* 2015;8:12956–62.
147. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. *Cancer Lett* 2013;339:159–66.
148. Wang X, Sun W, Shen W, Xia M, Chen C, Xiang D, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. *J Hepatol* 2016;64:1283–94.
149. Sahu A, Singhal U, Chinnaiyan AM. Long noncoding RNAs in cancer: from function to translation. *Trends Cancer* 2015;1:93–109.
150. Zhang SR, Yang JK, Xie JK, Zhao LC. Long noncoding RNA HOTTIP contributes to the progression of prostate cancer by regulating HOXA13. *Cell Mol Biol (Noisy-le-grand)* 2016;62:84–8.
151. Li Z, Zhao X, Zhou Y, Liu Y, Zhou Q, Ye H, et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. *J Transl Med* 2015;13:84.
152. Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. *Hepatology* 2014;59:911–23.
153. Huang M, Zhong Z, Lv M, Shu J, Tian Q, Chen J. Comprehensive analysis of differentially expressed profiles of lncRNAs and circRNAs with associated co-expression and ceRNA networks in bladder carcinoma. *Oncotarget* 2016;7:47186–200.
154. Droop J, Szarvas T, Schulz WA, Niedworok C, Niegisch G, Scheckenbach K, et al. Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma. *PLoS One* 2017;12:e0176287.
155. Terracciano D, Ferro M, Terreri S, Lucarelli G, D'Elia C, Musi G, et al. Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. *Transl Res* 2017;184:108–17.

156. Chen P, Wan D, Zheng D, Zheng Q, Wu F, Zhi Q. Long non-coding RNA UCA1 promotes the tumorigenesis in pancreatic cancer. *Biomed Pharmacother* 2016;83:1220–6.
157. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. *FEBS J* 2014;281:1750–8.
158. Liu H, Wang G, Yang L, Qu J, Yang Z, Zhou X. Knockdown of long non-coding RNA UCA1 increases the tamoxifen sensitivity of breast cancer cells through inhibition of Wnt/beta-catenin pathway. *PLoS One* 2016;11:e0168406.
159. Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. *Cell Stem Cell* 2015;16:413–25.
160. Hu S, Shan G. LncRNAs in stem cells. *Stem Cells Int* 2016;2016:2681925.
161. Wei S, Wang K. Long noncoding RNAs: pivotal regulators in acute myeloid leukemia. *Exp Hematol Oncol* 2015;5:30.
162. Alvarez-Dominguez JR, Hu W, Gromatzky AA, Lodish HF. Long noncoding RNAs during normal and malignant hematopoiesis. *Int J Hematol* 2014;99:531–41.
163. Hu W, Yuan B, Flygare J, Lodish HF. Long noncoding RNA-mediated anti-apoptotic activity in murine erythroid terminal differentiation. *Genes Dev* 2011;25:2573–8.
164. Mertens D, Philippen A, Ruppel M, Allegra D, Bhattacharya N, Tschuch C, et al. Chronic lymphocytic leukemia and 13q14: miRs and more. *Leuk Lymphoma* 2009;50:502–5.
165. Garding A, Bhattacharya N, Claus R, Ruppel M, Tschuch C, Filarsky K, et al. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the lnc Cis downregulation of a gene cluster that targets NF-kB. *PLoS Genet* 2013;9:e1003373.
166. Trimarchi T, Bilal E, Ntziachristos P, Fabbri G, Dalla-Favera R, Tsigiris A, et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. *Cell* 2014;158:593–606.
167. Peng W, Feng J. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. *Biomed Pharmacother* 2016;77:65–71.
168. Guo G, Kang Q, Zhu X, Chen Q, Wang X, Chen Y, et al. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. *Oncogene* 2015;34:1768–79.
169. Xia T, Chen S, Jiang Z, Shao Y, Jiang X, Li P, et al. Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. *Sci Rep* 2015;5:13445.
170. Wan L, Kong J, Tang J, Wu Y, Xu E, Lai M, et al. HOTAIRM1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumour suppressor. *J Cell Mol Med* 2016;20:2036–44.
171. Wang XQ, Dostie J. Reciprocal regulation of chromatin state and architecture by HOTAIRM1 contributes to temporal collinear HOXA gene activation. *Nucleic Acids Res* 2016;45:1091–104.
172. Zhang X, Weissman SM, Newburger PE. Long intergenic non-coding RNA HOTAIRM1 regulates cell cycle progression during myeloid maturation in NB4 human promyelocytic leukemia cells. *RNA Biol* 2014;11:777–87.
173. Wei S, Zhao M, Wang X, Li Y, Wang K. PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation. *J Hematol Oncol* 2016;9:44.
174. Cerase A, Pintacuda G, Tattermusch A, Avner P. Xist localization and function: new insights from multiple levels. *Genome Biol* 2015;16:166.
175. Huang KC, Rao PH, Lau CC, Heard E, Ng SK, Brown C, et al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. *Mol Cancer Ther* 2002;1:769–76.
176. Wang F, Li X, Xie X, Zhao L, Chen W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. *FEBS Lett* 2008;582:1919–27.
177. Kladi-Skandali A, Michaelidou K, Scorilas A, Mavridis K. Long noncoding RNAs in digestive system malignancies: a novel class of cancer biomarkers and therapeutic targets? *Gastroenterol Res Pract* 2015;2015:319861.
178. Tahira AC, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS, Maracaja-Coutinho V, et al. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. *Mol Cancer* 2011;10:141.
179. Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. *Nat Genet* 2010;42:1113–7.
180. Huang X, Zhi X, Gao Y, Ta N, Jiang H, Zheng J. LncRNAs in pancreatic cancer. *Oncotarget* 2016;7:57379–90.
181. Peng JF, Zhuang YY, Huang FT, Zhang SN. Noncoding RNAs and pancreatic cancer. *World J Gastroenterol* 2016;22:801–14.
182. Ren C, Li X, Wang T, Wang G, Zhao C, Liang T, et al. Functions and mechanisms of long noncoding RNAs in ovarian cancer. *Int J Gynecol Cancer* 2015;25:566–9.
183. Zhong Y, Gao D, He S, Shuai C, Peng S. Dysregulated expression of long noncoding RNAs in ovarian cancer. *Int J Gynecol Cancer* 2016;26:1564–70.
184. Meryet-Figuere M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L, et al. An overview of long non-coding RNAs in ovarian cancers. *Oncotarget* 2016;7:44719–34.
185. Blondeau JJ, Deng M, Syring I, Schrodter S, Schmidt D, Perner S, et al. Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. *Clin Epigenetics* 2015;7:10.
186. Seles M, Hutterer GC, Kiesslich T, Pummer K, Berindan-Neagoe I, Perakis S, et al. Current insights into long non-coding RNAs in renal cell carcinoma. *Int J Mol Sci* 2016;17:573.
187. Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in prostate, bladder, and kidney cancer. *Eur Urol* 2014;65:1140–51.
188. Gu W, Gao T, Sun Y, Zheng X, Wang J, Ma J, et al. LncRNA expression profile reveals the potential role of lncRNAs in gastric carcinogenesis. *Cancer Biomark* 2015;15:249–58.
189. Wan X, Ding X, Chen S, Song H, Jiang H, Fang Y, et al. The functional sites of miRNAs and lncRNAs in gastric carcinogenesis. *Tumour Biol* 2015;36:521–32.
190. Zhang E, He X, Yin D, Han L, Qiu M, Xu T, et al. Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57. *Cell Death Dis* 2016;7:e2109.
191. Fang XY, Pan HF, Leng RX, Ye DQ. Long noncoding RNAs: novel insights into gastric cancer. *Cancer Lett* 2015;356:357–66.
192. Kraus TF, Greiner A, Guibourt V, Lisek K, Kretzschmar HA. Identification of stably expressed lncRNAs as valid endogenous controls for profiling of human glioma. *J Cancer* 2015;6:111–9.
193. Jiang C, Li X, Zhao H, Liu H. Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis. *Mol Cancer* 2016;15:62.
194. Wang P, Ren Z, Sun P. Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. *J Cell Biochem* 2012;113:1868–74.
195. Qiao Q, Li H. LncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. *Biochem Biophys Res Commun* 2016;478:507–12.
196. Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. *Cancer Cell* 2014;26:722–37.
197. Xue S, Li QW, Che JP, Guo Y, Yang FQ, Zheng JH. Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma. *Int J Clin Exp Pathol* 2015;8:3765–74.
198. Guo C, Song WQ, Sun P, Jin L, Dai HY. LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. *J Biomed Sci* 2015;22:100.
199. Isin M, Uysaler E, Ozgur E, Koseoglu H, Sanli O, Yucel OB, et al. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease. *Front Genet* 2015;6:168.
200. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is down-regulated in breast cancer. *Oncogene* 2009;28:195–208.
201. Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. *Nature* 2012;488:111–5.
202. Li W, Zhai L, Wang H, Liu C, Zhang J, Chen W, et al. Downregulation of lncRNA GAS5 causes trastuzumab resistance in breast cancer. *Oncotarget* 2016;7:27778–86.
203. Pickard MR, Williams GT. Molecular and Cellular Mechanisms of Action of Tumour Suppressor GAS5 lncRNA. *Genes* 2015;6:484–99.



204. Yan R, Wang K, Peng R, Wang S, Cao J, Wang P, et al. Genetic variants in lncRNA SRA and risk of breast cancer. *Oncotarget* 2016;7:22486–96.
205. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat-containing RNA and RNA surveillance factors at mammalian chromosome ends. *Science* 2007;318:798–801.
206. Deng Z, Norseen J, Wiedmer A, Riethman H, Lieberman PM. TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. *Mol Cell* 2009;35:403–13.
207. Maicher A, Kastner L, Luke B. Telomeres and disease: enter TERRA. *RNA Biol* 2012;9:843–9.
208. Arora R, Brun CM, Azzalin CM. TERRA: long noncoding RNA at eukaryotic telomeres. *Prog Mol Subcell Biol* 2011;51:65–94.
209. Thorenor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. *Oncotarget* 2016;7:622–37.
210. Nie F, Yu X, Huang M, Wang Y, Xie M, Ma H, et al. Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression. *Oncotarget*. 2016 May 26. [Epub ahead of print].
211. Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, et al. Amplification of long noncoding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma. *Cancer Res* 2015;75:3181–91.
212. Askarian-Amiri ME, Crawford J, French JD, Smart CE, Smith MA, Clark MB, et al. SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. *RNA* 2011;17:878–91.
213. Colombo T, Farina L, Macino G, Paci P. PVT1: a rising star among oncogenic long noncoding RNAs. *Biomed Res Int* 2015;2015:304208.
214. Kong R, Zhang EB, Yin DD, You LH, Xu TP, Chen WM, et al. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. *Mol Cancer* 2015;14:82.
215. Liu E, Liu Z, Zhou Y, Mi R, Wang D. Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. *Int J Clin Exp Med* 2015;8:20565–72.
216. You L, Chang D, Du HZ, Zhao YP. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. *Biochem Biophys Res Commun* 2011;407:1–6.
217. Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS. The lncRNA PVT1 contributes to the cervical cancer phenotype and associates with poor patient prognosis. *PLoS One* 2016;11:e0156274.
218. Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, et al. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. *J Clin Endocrinol Metab* 2008;93:4119–25.
219. Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, et al. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. *Genes Cells* 2000;5:211–20.
220. Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. *Cancer Res* 2010;70:2350–8.
221. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, et al. Activation of p53 by MEG3 non-coding RNA. *J Biol Chem* 2007;282:24731–42.
222. Ying L, Huang Y, Chen H, Wang Y, Xia L, Chen Y, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. *Mol Biosyst* 2013;9:407–11.
223. Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, et al. MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triplex structures. *Nat Commun* 2015;6:7743.
224. Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. *Biochem Biophys Res Commun* 2014;455:43–57.
225. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeny LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. *Cancer Res* 2002;62:2695–8.
226. Ilboudo A, Chouhan J, McNeil BK, Osborne JR, Ogunwobi OO. PVT1 exon 9: a potential biomarker of aggressive prostate cancer? *Int J Environ Res Public Health* 2015;13:ijerph13010012.
227. Orfanelli U, Jachetti E, Chiacchiera F, Grioni M, Brambilla P, Briganti A, et al. Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. *Oncogene* 2015;34:2094–102.
228. Zhang L, Song X, Wang X, Xie Y, Wang Z, Xu Y, et al. Circulating DNA of HOTAIR in serum is a novel biomarker for breast cancer. *Breast Cancer Res Treat* 2015;152:199–208.
229. Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu KD, et al. Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value. *Cancer Res* 2016;76:2105–14.
230. ClinicalTrials.gov. TA(E)C-GP versus A(E)C-T for the high risk TNBC patients and validation of the mRNA-lncRNA signature. Available from: <https://ClinicalTrials.gov/show/NCT02641847>.
231. Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jockel KH, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. *BMC Res Notes* 2013;6:518.
232. Guo F, Yu F, Wang J, Li Y, Li Z, et al. Expression of MALAT1 in the peripheral whole blood of patients with lung cancer. *Biomed Rep* 2015;3:309–12.
233. Wang HM, Lu JH, Chen WY, Gu AQ. Upregulated lncRNA-UCA1 contributes to progression of lung cancer and is closely related to clinical diagnosis as a predictive biomarker in plasma. *Int J Clin Exp Med* 2015;8:11824–30.
234. Xue Y, Gu D, Ma G, Zhu L, Hua Q, Chu H, et al. Genetic variants in lncRNA HOTAIR are associated with risk of colorectal cancer. *Mutagenesis* 2015;30:303–10.
235. Zhao W, Song M, Zhang J, Kuerban M, Wang H. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. *Int J Clin Exp Pathol* 2015;8:14131–40.
236. Yue B, Sun B, Liu C, Zhao S, Zhang D, Yu F, et al. Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. *Cancer Sci* 2015;106:1323–32.
237. Shi J, Li X, Zhang F, Zhang C, Guan Q, Cao X, et al. Circulating lncRNAs associated with occurrence of colorectal cancer progression. *Am J Cancer Res* 2015;5:2258–65.
238. Li J, Wang X, Tang J, Jiang R, Zhang W, Ji J, et al. HULC and linc00152 act as novel biomarkers in predicting diagnosis of hepatocellular carcinoma. *Cell Physiol Biochem* 2015;37:687–96.
239. Tang J, Jiang R, Deng L, Zhang X, Wang K, Sun B. Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma. *Oncotarget* 2015;6:4505–15.
240. Wang F, Ren S, Chen R, Lu J, Shi X, Zhu Y, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. *Oncotarget* 2014;5:11091–102.
241. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived mini-RNA as a novel plasma-based biomarker for diagnosing prostate cancer. *Eur J Cancer* 2013;49:2949–59.
242. Xu N, Chen F, Wang F, Lu X, Wang X, Lv M, et al. Clinical significance of high expression of circulating serum lncRNA RP11-445H22.4 in breast cancer patients: a Chinese population-based study. *Tumour Biol* 2015;36:7659–65.
243. Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW, Li MQ, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. *Clin Cancer Res* 2006;12:4851–8.
244. Shang C, Guo Y, Zhang H, Xue YX. Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma. *Cancer Chemother Pharmacol* 2016;77:507–13.
245. Melo CP, Campos CB, Rodrigues Jde O, Aguirre-Neto JC, Atalla A, Pianovski MA, et al. Long non-coding RNAs: biomarkers for acute leukaemia subtypes. *Br J Haematol* 2016;173:318–20.
246. Chen ZJ, Zhang Z, Xie BB, Zhang HY. Clinical significance of up-regulated lncRNA NEAT1 in prognosis of ovarian cancer. *Eur Rev Med Pharmacol Sci* 2016;20:3373–7.
247. Wu Y, Wang YQ, Weng WW, Zhang QY, Yang XQ, Gan HL, et al. A serum-circulating long noncoding RNA signature can discriminate between

- patients with clear cell renal cell carcinoma and healthy controls. *Oncogenesis* 2016;5:e192.
248. Li J, Wang Y, Yu J, Dong R, Qiu H. A high level of circulating HOTAIR is associated with progression and poor prognosis of cervical cancer. *Tumour Biol* 2015;36:1661–5.
  249. Tong YS, Wang XW, Zhou XL, Liu ZH, Yang TX, Shi WH, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. *Mol Cancer* 2015;14:3.
  250. Zhou X, Yin C, Dang Y, Ye F, Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. *Sci Rep* 2015;5:11516.
  251. Pang Q, Ge J, Shao Y, Sun W, Song H, Xia T, et al. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. *Tumour Biol* 2014;35:5441–7.
  252. Zheng Q, Wu F, Dai WY, Zheng DC, Zheng C, Ye H, et al. Aberrant expression of UCA1 in gastric cancer and its clinical significance. *Clin Transl Oncol* 2015;17:640–6.
  253. Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, et al. Circulating CUDR, LINC1-5 and PIENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. *Int J Cancer* 2015;137:1128–35.
  254. Shao Y, Ye M, Jiang X, Sun W, Ding X, Liu Z, et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. *Cancer* 2014;120:3320–8.
  255. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat Rev Drug Discov* 2013;12:847–65.
  256. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. *Nat Struct Mol Biol* 2013;20:300–7.
  257. ClinicalTrials.gov. A study on the gastrointestinal disease and *Helicobacter pylori* controlled long non-coding RNA. Available from: <https://ClinicalTrials.gov/show/NCT03057171>.
  258. Bourdumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, Deliveliotis C. The novel prostate cancer antigen 3 (PCA3) biomarker. *Int Braz J Urol* 2010;36:665–8.
  259. Li C, Yang L, Lin C. Long noncoding RNAs in prostate cancer: mechanisms and applications. *Mol Cell Oncol* 2014;1:e963469.
  260. Shi L, Peng F, Tao Y, Fan X, Li N. Roles of long noncoding RNAs in hepatocellular carcinoma. *Virus Res* 2016;223:131–9.
  261. Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J, et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. *PLoS One* 2012;7:e35145.
  262. Ishibashi M, Kogo R, Shibata K, Sawada G, Takahashi Y, Kurashige J, et al. Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. *Oncol Rep* 2013;29:946–50.
  263. Lavorgna G, Vago R, Sarmini M, Montorsi F, Salonia A, Bellone M. Long non-coding RNAs as novel therapeutic targets in cancer. *Pharmacol Res* 2016;110:131–8.
  264. Matsui M, Corey DR. Non-coding RNAs as drug targets. *Nat Rev Drug Discov* 2017;16:167–79.
  265. Cai Y, He J, Zhang D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. *Onco Targets Ther* 2015;8:2657–64.
  266. Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, et al. Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2. *Mol Cell* 2016;61:520–34.
  267. Zheng J, Zhao S, He X, Zheng Z, Bai W, Duan Y, et al. The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition. *Biochem Biophys Res Commun* 2016;480:508–14.
  268. Johnstone KA, DuBose AJ, Futtner CR, Elmore MD, Brannan CI, Resnick JL. A human imprinting centre demonstrates conserved acquisition but diverged maintenance of imprinting in a mouse model for Angelman syndrome imprinting defects. *Hum Mol Genet* 2006;15:393–404.
  269. Tan WH, Bird LM. Pharmacological therapies for Angelman syndrome. *Wien Med Wochenschr* 2017;167:205–18.
  270. Scaiewicz V, Sorin V, Fellig Y, Birman T, Mizrahi A, Galula J, et al. Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer. *J Oncol* 2010;2010:178174.
  271. Chen H, Xin Y, Zhou L, Huang JM, Tao L, Cheng L, et al. Cisplatin and paclitaxel target significant long noncoding RNAs in laryngeal squamous cell carcinoma. *Med Oncol* 2014;31:246.
  272. Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. *Oncogene* 2016;35:2746–55.
  273. Zhao W, Dong S, Duan B, Chen P, Shi L, Gao H, et al. HOTAIR is a predictive and prognostic biomarker for patients with advanced gastric adenocarcinoma receiving fluorouracil and platinum combination chemotherapy. *Am J Transl Res* 2015;7:1295–302.
  274. Fang S, Gao H, Tong Y, Yang J, Tang R, Niu Y, et al. Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells. *Lab Invest* 2016;96:60–8.
  275. Han Y, Liu Y, Gui Y, Cai Z. Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. *J Surg Oncol* 2013;107:555–9.
  276. Young TL, Matsuda T, Cepko CL. The noncoding RNA Taurine upregulated gene 1 is required for differentiation of the murine retina. *Curr Biol* 2005;15:501–12.
  277. Li Z, Shen J, Chan MT, Wu WK. TUG1: a pivotal oncogenic long non-coding RNA of human cancers. *Cell Prolif* 2016;49:471–5.
  278. Niu Y, Ma F, Huang W, Fang S, Li M, Wei T, et al. Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2. *Mol Cancer* 2017;16:5.
  279. Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/beta-catenin signaling. *Mol Cancer* 2017;16:9.
  280. Li Z, Zhao L, Wang Q. Overexpression of long non-coding RNA HOTTIP increases chemoresistance of osteosarcoma cell by activating the Wnt/beta-catenin pathway. *Am J Transl Res* 2016;8:2385–93.
  281. Liu X, Jiao T, Wang Y, Su W, Tang Z, Han C. Long non-coding RNA GAS5 acts as a molecular sponge to regulate miR-23a in gastric cancer. *Minerva Med.* 2016 Nov 9. [Epub ahead of print].
  282. Chen W, Xu XK, Li JL, Kong KK, Li H, Chen C, et al. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. *Oncotarget* 2017;8:22783–99.
  283. Zhu KP, Zhang CL, Shen GQ, Zhu ZS. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis. *Int J Clin Exp Pathol* 2015;8:8754–73.
  284. Zhang CL, Zhu KP, Shen GQ, Zhu ZS. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma. *Tumour Biol* 2016;37:2737–48.
  285. Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang E, et al. LncRNA H19 confers chemoresistance in ERalpha-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. *Oncotarget* 2016;7:81452–62.
  286. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. *Nat Rev Drug Discov* 2013;12:433–46.
  287. Alvarez-Dominguez JR, Bai Z, Xu D, Yuan B, Lo KA, Yoon MJ, et al. De Novo Reconstruction of Adipose Tissue Transcriptomes Reveals Long Non-coding RNA Regulators of Brown Adipocyte Development. *Cell Metab* 2015;21:764–76.
  288. Knoll M, Lodish HF, Sun L. Long non-coding RNAs as regulators of the endocrine system. *Nat Rev Endocrinol* 2015;11:151–60.
  289. Sun L, Goff LA, Trapnell C, Alexander R, Lo KA, Hacisuleyman E, et al. Long noncoding RNAs regulate adipogenesis. *Proc Natl Acad Sci U S A* 2013;110:3387–92.
  290. Alvarez-Dominguez JR, Hu W, Yuan B, Shi J, Park SS, Gromatzky AA, et al. Global discovery of erythroid long noncoding RNAs reveals novel regulators of red cell maturation. *Blood* 2014;123:570–81.
  291. Baldassarre A, Masotti A. Long non-coding RNAs and p53 regulation. *Int J Mol Sci* 2012;13:16708–17.
  292. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. *Nat Rev Genet* 2016;17:47–62.